(12) International Application Status Report

Received at International Bureau: 08 May 2020 (08.05.2020)

Information valid as of: 12 November 2020 (12.11.2020)

Report generated on: 06 March 2021 (06.03.2021)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2020/22332705 November 2020 (05.11.2020) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/US2020/03043529 April 2020 (29.04.2020) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
62/840,774 (US)30 April 2019 (30.04.2019) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
C07K 16/28 (2006.01); C07K 16/46 (2006.01); C12N 5/0783 (2010.01); A61K 35/28 (2015.01); A61K 39/395 (2006.01); A61P 35/02 (2006.01)

(71) Applicant(s):
ATARA BIOTHERAPEUTICS, INC. [US/US]; 611 Gateway Blvd., Suite 900 South San Francisco, CA 94080 (US) (for all designated states)

(72) Inventor(s):
AFTAB, Blake, T.; 611 Gateway Blvd., Suite 900 South San Francisco, CA 94080 (US)

(74) Agent(s):
HALSTEAD, David, P.; Patent Group FOLEY HOAG LLP 155 Seaport Boulevard Boston, MA 02210-2600 (US)

(54) Title (EN): ANTIGEN SPECIFIC CD19-TARGETED CAR-T CELLS
(54) Title (FR): CELLULES CAR-T CIBLÉES PAR UN ANTIGÈNE CD19 SPÉCIFIQUE

(57) Abstract:
(EN): Disclosed are compositions and methods for targeted treatment of cancer, such as hematologic cancer. In particular, chimeric antigen receptor (CAR) T cells are disclosed that can be used with adoptive cell transfer to target and kill cancer cells with reduced antigen escape. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with hematologic cancer that involves adoptive transfer of the disclosed CAR T cells.
(FR): La présente invention concerne des compositions et des méthodes de traitement ciblé de cancers, notamment le cancer hématologique. En particulier, l'invention concerne des cellules T à récepteurs antigéniques chimériques (CAR) qui peuvent être utilisés dans le transfert adoptif de cellules pour cibler et éliminer des cellules cancéreuses avec un échappement antigénique réduit. L'invention concerne par ailleurs des procédés consistant à conférer une immunité anti-tumorale à un sujet atteint d'un cancer hématologique impliquant un transfert adoptif des cellules CAR-T décrites.

International search report:
Received at International Bureau: 27 July 2020 (27.07.2020) [IL]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:
Declaration of inventorship (Rules 4.17(iv) and 51bis.1(a)(iv)) for the purposes of the designation of the United States of America